ClinicalTrials.gov
ClinicalTrials.gov Menu

TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02060006
Recruitment Status : Unknown
Verified April 2014 by Prof Jean Nachega, University of Stellenbosch.
Recruitment status was:  Recruiting
First Posted : February 11, 2014
Last Update Posted : April 3, 2014
Sponsor:
Collaborator:
University of Pittsburgh
Information provided by (Responsible Party):
Prof Jean Nachega, University of Stellenbosch

February 7, 2014
February 11, 2014
April 3, 2014
April 2014
April 2015   (Final data collection date for primary outcome measure)
Incidence of TB IRIS [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT02060006 on ClinicalTrials.gov Archive Site
  • Proportion discontinuing Meloxicam due to adverse event [ Time Frame: 6 months ]
  • The proportion of patients in each arm with the following indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort >III [ Time Frame: 6 months ]
  • The proportion of patients with local or disseminated suppuration/abscess of any site, unscheduled clinic visits, hospitalizations, missed more than a day at work, etc [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial
A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults

Background: Non-Steroid Anti-Inflammatory Drugs (NSAIDs) reduce pain and inflammation by inhibiting cyclooxygenase, an enzyme in the pathway for formation of prostaglandins and thromboxane. Prior studies have proven the role of ibuprofen (an NSAID) in modulating lung injury and decreasing pulmonary damage in cystic fibrosis. While there has been an intense effort by the scientific community to define the best treatment strategies for tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS), to our knowledge there is no available study evaluating preventive strategies using anti-inflammatory agents for TB-IRIS, a highly morbid complication in HIV-infected TB patients initiating antiretroviral therapy (ART).

Design and Methods: We propose to conduct a single center double-blind placebo-controlled randomized trial to investigate the efficacy of daily self-administered Meloxicam (a NSAID) versus placebo for prevention of Tuberculosis associated Immune Reconstitution Inflammatory Syndrome (TB-IRIS). A total of 150 HIV-infected adults who are treated for Tuberculosis for at least 2 weeks and about to initiate HIV treatment at Brewelskloof Hospital, Worcester, and Tygerberg Teaching Hospital, Cape Town, will be randomized to one of the following treatments: Meloxicam 7.5 mg tablet once-a-day, the experimental arm, versus Placebo tablet once-a-day, the control arm, for 8 weeks. All patients will be followed up for 12 months. Primary efficacy outcome: The decrease of the incidence of paradoxical TB IRIS by at least 20%; Primary safety outcome: The proportion of patients who temporarily or permanently discontinue Meloxicam due to any adverse event (e.g. dyspepsia or gastro-intestinal upset). Secondary outcomes are: 1) the proportion of patients in each arm with the following indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort >III, presence of local or disseminated suppuration/abscess of any site, unscheduled clinic visits, hospitalizations, missed more than a day at work, etc; 2) The incidence of other types of IRIS (e.g. Kaposi Sarcoma or cryptococcal meningitis).

This study will provide important and novel data on the feasibility and efficacy of using a cheap, widely available NSAID used in both developed and developing countries, as a preventive intervention for TB-IRIS that could be quickly put into practice if proven to be effective

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Tuberculosis
Drug: Meloxicam 7.5mg daily for 8 weeks
Meloxicam 7.5mg daily for 8 weeks
Other Name: Cox-2 Inhibitor
  • Placebo Comparator: Placebo 7.5 mg daily for 8 weeks
    Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
  • Experimental: Meloxicam 7.5 mg once-daily
    Meloxicam 7.5mg once-daily for 8 weeks
    Intervention: Drug: Meloxicam 7.5mg daily for 8 weeks

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
200
Same as current
April 2015
April 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and non-pregnant females age 18 years of age or older
  • Evidence of HIV-1 infection
  • TB treatment (<2 weeks) and initiating EFV-based antiretroviral therapy as per the South African Department of Health Guidelines
  • Living in the study site catchment area and having had a known address for more than 3 months
  • Written informed consent

Exclusion Criteria:

  • History of aspirin sensitivity and allergies to other NSAIDs
  • Current or recent use (<3 months) of aspirin, NSAIDs, or anticoagulants such as warfarin.
  • Current or recent use of corticosteroid therapy
  • History of gastro-intestinal bleeding or peptic ulcer
  • History of cardiovascular thrombotic events (myocardial infarction or stroke), hypertension, or congestive heart failure
  • Severe renal impairment as evidenced by creatinine clearance <50 (Cockcroft- Gault Formula)
  • Severe liver disease (ALT > five times upper limit of normal)
  • Presence of a medical condition likely to result in death within 6 months from start of ART. These conditions include suspected or CNS lymphoma, PMLE and disseminated visceral Kaposi's sarcoma
  • Cognitive disorder(s) that could impair ability to comply with study requirements, as determined by the study physician
  • Karnofsky performance score <60
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
South Africa
 
 
NCT02060006
PRO13060453
Yes
Not Provided
Not Provided
Prof Jean Nachega, University of Stellenbosch
University of Stellenbosch
University of Pittsburgh
Not Provided
University of Stellenbosch
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP